Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951656 | 0.69 | ENPP2 (0.44) | ENPP2 | |
| SCHEMBL9004978 | 0.67 | — | — | |
| SCHEMBL1992222 | 0.67 | — | — | |
| SCHEMBL1492367 | 0.67 | — | — | |
| SCHEMBL660071 | 0.65 | — | — | |
| SCHEMBL1538831 | 0.65 | — | — | |
| SCHEMBL3189246 | 0.65 | — | — | |
| SCHEMBL436505 | 0.65 | — | — | |
| SCHEMBL15287122 | 0.65 | — | — | |
| SCHEMBL2403742 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055114-A1 | IMIDAZO[1,2-B]PYRIDAZINE INHIBITORS OF CYCLIN-DEPENDENT KINASES | H LEE MOFFITT CANCER CT & RES (US) | 2026-02-26 | — | — | US | disclosed |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PFIZER INC. (US) | 2024-07-25 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PREP, PEPD, ACE | ENPP2 2307/4885IKBKB 1922/4885TRPA1 2365/4885 |
| US-20260055114-A1 | IMIDAZO[1,2-B]PYRIDAZINE INHIBITORS OF CYCLIN-DEPENDENT KINASES | CCNC, CDK1, CDK3 | ENPP2 3098/4885IKBKB 343/4885TRPA1 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.